Neuroleptic Malignant Syndrome

Epidemiology & Etiology

NMS is a medical emergency most commonly triggered by high-potency first-generation antipsychotics (e.g., haloperidol), though second-generation agents and antiemetics (e.g., metoclopramide) can also cause it. It can paradoxically occur following abrupt withdrawal of dopamine agonists (e.g., levodopa) in Parkinson disease. Risk factors include rapid dose escalation, parenteral administration, and dehydration. Prior episodes significantly increase the risk of recurrence, making re-challenge highly risky.

Pertinent Anatomy

The pathology centers on the hypothalamus, which regulates core body temperature and autonomic tone. Additionally, the nigrostriatal pathway in the basal ganglia is implicated, where dopamine blockade leads to profound motor abnormalities.

Pathophysiology

The primary mechanism is sudden, profound central dopamine D2 receptor blockade or dopamine depletion. Blockade in the hypothalamus disrupts the thermoregulatory set-point, causing severe hyperthermia and autonomic dysregulation. Concurrent D2 blockade in the nigrostriatal pathway induces severe extrapyramidal symptoms, manifesting as muscle rigidity. This sustained muscular contraction generates excess heat and causes muscle breakdown, leading to rhabdomyolysis.

Clinical Manifestations

Symptoms typically evolve over 1-3 days, presenting with the classic tetrad. The earliest sign is often altered mental status, ranging from delirium to coma. This is followed by profound "lead-pipe" muscle rigidity and hyporeflexia. Autonomic instability manifests as tachycardia, labile blood pressure, profound diaphoresis, and tachypnea. Hyperthermia is a hallmark, with temperatures frequently exceeding 104°F (40°C).

Diagnosis

Diagnosis is primarily clinical based on the history of dopamine antagonist exposure and the classic tetrad. Laboratory hallmarks include a profoundly elevated creatine kinase (CK), often >1000 U/L, indicating severe muscle breakdown. Additional findings include leukocytosis with a left shift, and elevated hepatic transaminases. Urinalysis may reveal myoglobinuria, a critical warning sign for impending acute kidney injury.

Treatment

The absolute most critical step is immediate discontinuation of the offending agent. First-line management involves aggressive supportive care: IV fluids for cooling and renal protection, and cooling blankets. For moderate to severe cases, pharmacological intervention includes bromocriptine (a dopamine agonist) or amantadine. Dantrolene, a direct-acting muscle relaxant that inhibits calcium release from the sarcoplasmic reticulum, is reserved for severe rigidity and hyperthermia. Avoid restarting the same antipsychotic; if necessary later, wait at least two weeks and use a low-potency atypical agent.

Prognosis

Untreated NMS carries a mortality rate of 10-20%, but early recognition significantly improves outcomes. The most common fatal complications are rhabdomyolysis leading to acute renal failure, and cardiopulmonary arrest. Patients require prolonged monitoring as symptoms can last 1-2 weeks after discontinuing oral medications, and even longer for depot injections.

Differential Diagnosis